Newsletter December 2020

2020 has been a difficult year for everyone. However, despite the many…

Av Lucie van Leeuwen.Publicerad January 6, 2021
Newsletter December 2020

2020 has been a difficult year for everyone. However, despite the many challenges, we can also look back on some milestone achievements. In our latest newsletter, we review some of our major highlights. Click the link to read our newsletter: http://bit.ly/3njT6nQ

Would you like to receive our next newsletter in your email? You can subscribe here: https://www.tricals.org/subscribe-to-our-newsletter/

We look forward to the new year in which we will undoubtedly achieve even more together. Together we will build our highway towards new therapies for ALS.


Dela

Relaterade nyheter

ATLAS-studien – en klinisk stgnudie för personer som vill bidra till forskningen kring SOD1 i samband med ALS
ATLAS-studien – en klinisk stgnudie för personer som vill bidra till forskningen kring SOD1 i samband med ALS
Biogen genomför en klinisk studie för att bedöma effektiviteten och säkerheten hos […]
Food and Drug Administration (FDA) godkänner AMX0035 (Amylyx) för den amerikanska marknaden
Food and Drug Administration (FDA) godkänner AMX0035 (Amylyx) för den amerikanska marknaden
Under ett möte i FDAs rådgivande kommitté för perifera och centrala nervsystemet […]
Measuring treatment effects based on patient preference
Measuring treatment effects based on patient preference
To evaluate the effect of an investigational drug in ALS clinical trials, […]
TRICALS Enrols First Participants in Phase 3 MAGNET platform trial for ALS
TRICALS Enrols First Participants in Phase 3 MAGNET platform trial for ALS
TRICALS (the Treatment Research Initiative to Cure ALS), in collaboration with ALS […]